Comparison of pathogenic factors expressed by group A Streptococci isolated from patients with streptococcal toxic shock syndrome and scarlet fever

Microbial Pathogenesis

Volumn 27, Issue 4, 1999, Pages 243-252

  Shiseki, Masayuki ^a   Miwa, Keishi ^b   Nemoto, Yuko ^c   Kato, Hideto ^a   Suzuki, Jun ^d   Sekiya, Kachiko ^e   Murai, Teiko ^f   Kikuchi, Tatsuo ^g   Yamashita, Naoya ^h   Totsuka, Kyoichi ^a   Ooe, Kenji ⁱ   Shimizu, Yoshikata ⁱ   Uchiyama, Takehiko ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b IWATE MEDICAL UNIVERSITY   (Japan)

^c TORAY INDUSTRIES INC   (Japan)

^d AZABU UNIVERSITY   (Japan)

^e KITASATO UNIVERSITY   (Japan)

^f TOHO UNIVERSITY   (Japan)

^g Kikuchi Clinic   (Japan)

^h KEIO UNIVERSITY   (Japan)

ⁱ ASAHI GENERAL HOSPITAL   (Japan)

Author keywords

Lethal activity; Streptococcal toxic shock syndrome; Streptolysin O

Indexed keywords

CYSTEINE PROTEINASE; EXOTOXIN; STREPTOLYSIN O;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MALE; MORTALITY; MOUSE; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PRIORITY JOURNAL; SCARLET FEVER; STREPTOCOCCUS GROUP A; TOXIC SHOCK SYNDROME;

ANIMALIA; BACTERIA (MICROORGANISMS); STREPTOCOCCUS GROUP A; STREPTOCOCCUS SP. 'GROUP A';

EID: 0032824969     PISSN: 08824010     EISSN: None     Source Type: Journal    
DOI: 10.1006/mpat.1999.0302     Document Type: Article

References (44)

1. Cone LA, Woodard DR, Schlievert PM, Tomory GS. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med. 317:1987;146-149.
2. Stevens DL, Tanner MH, Winship J, Swarts R, Ries KM, Schlievert PM, Kaplan E. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med. 321:1989;1-7.
3. Stevens DL. Invasive group A streptococcus infections. Clin Infect Dis. 14:1992;2-11.
4. Hoge CW, Schwartz B, Talkington DF, Breiman RF, MacNeill EM, Englender SJ. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococci toxic shock-like syndrome. JAMA. 269:1993;384-389.
5. Stevens DL. Streptococcal toxic-shock syndrome: Spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis. 1:1995;69-78.
6. Shimizu Y, Ohyama A, Kasama K, Miyazaki M, Ooe K, Ookochi Y. Case report of toxic shock-like syndrome due to group A streptococcal infection. Kansenshogaku Zasshi. 67:1993;236-9 (in Japanese).
7. Shimizu Y, Ooe K. Clinical and pathological study of cases with severe type GAS infection. Asahi Cho Ihou. 16:1994;476-501 (in Japanese).
8. Ooe K, Udagawa H. A new type of fulminant group A streptococcal infection in obstetrics patients: Report of two cases. Humn Pathol. 28:1997;509-512.
9. The Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome. JAMA. 269:1993;390-391.
10. Todd J, Fishaut M, Kapral F, Welch T. Toxic-shock syndrome associated with phage-group-I staphylococci. Lancet. 2:1978;1116-1118.
11. Davis JP, Chesney PJ, Wand PJ, LaVenture M. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med. 303:1980;1429-1435.
12. Tofte RW, Williams DN. Clinical and laboratory manifestations of toxic shock syndrome. Ann Intern Med. 96:1982;843-847.
13. Thompson A, Halbert SP, Smith U. The toxicity of streptolysin O for beating mammalian heart cells in tissue culture. J Exp Med. 131:1970;745-763.
14. Hirsch JG, Bernheimer AW, Weissman G. Motion picture study of the toxic action of streptolysins on leukocytes. J Exp Med. 118:1963;223-227.
15. Alouf JE. Streptococcal toxins (streptolysin O, streptolysin S, erythrogenic toxin). Pharmacol Ther. 11:1980;661-717.
16. Imanishi K, Igarashi H, Uchiyama T. Activation of murine T cells by streptococcal pyrogenic exotoxin A. Requirement for MHC class II molecules on accessory cells and identification of Vβ elements in T cell receptor of toxin-reactive T cells. J Immunol. 145:1990;3170-3176.
17. Abe J, Forrester J, Nakahara T, Lafferty JA, Kotzin BL, Leung DY. Selective stimulation of human T cells with streptococcal erythrogenic toxins A and B. J Immunol. 146:1991;3748-3750.
18. Imanishi K, Igarashi H, Uchiyama T. Relative abilities of distinct isotypes of human major histocompatibility complex class II molecules to bind streptococcal pyrogenic exotoxin types A and B. Infect Immun. 60:1992;5025-5029.
19. Kotzin BL, Leung DY, Kappler J, Marrack P. Superantigens and their potential role in human disease. Adv Immunol. 54:1993;99-166.
20. Uchiyama T, Yan XJ, Imanishi K, Yagi J. Bacterial superantigens-mechanism of T cell activation by the superantigens and their role in the pathogenesis of infectious diseases. Microbiol Immunol. 38:1994;245-256.
21. Shanley TP, Schrier D, Kapur V, Kehoe M, Musser JM, Ward PA. Streptococcal cysteine protease augments lung injury induced by products of group A streptococci. Infect Immun. 64:1996;870-877.
22. Berge A, Bjorck L. Streptococcal cysteine proteinase releases biologically active fragments of streptococcal surface proteins. J Biol Chem. 270:1995;9862-9867.
23. Herwald H, Collin M, Muller-Esterl W, Bjorck L. Streptococcal cystein proteinase releases kinins: a novel virulence mechanism. J Exp Med. 184:1996;665-673.
24. Doctor A, Harper MB, Fleisher GR. Group A β-hemolytic streptococcal bacteremia: historical overview, changing incidence, and recent association with varicella. Pediatrics. 96:1995;428-433.
25. Carapetis J, Robins-Browne R, Martin D, Shelby-James T, Hogg G. Increasing severity of invasive group A streptococcal disease in Australia: clinical and molecular epidemiological features and identification of a new virulent M-nontypable clone. Clin Infect Dis. 21:1995;1220-1227.
26. Lee PK, Schlievert PM. Quantification and toxicity of group A streptococcal pyrogenic exotoxins in an animal model of toxic shock syndrome-like illness. J Clin Microbiol. 27:1989;1890-1892.
27. Michie C, Scott A, Cheesbrough J, Beverley P, Pasvol G. Streptococcal toxic shock-like syndrome: evidence of superantigen activity and its effects on T lymphocyte subsets in vivo. Clin Exp Immunol. 98:1994;140-144.
28. Watanabe-Ohnishi R, Low DE, McGeer A, Stevens DL, Schlievert PM, Newton D, Schwartz B, Kreiswirth B, Kotb M. Selective depletion of Vβ-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. J Infect Dis. 171:1995;74-84.
29. Li PL, Tiedemann RE, Moffat SL, Fraser JD. The superantigen streptococcal pyrogenic exotoxin C (Spe-C) exhibits a novel mode of action. J Exp Med. 186:1997;375-383.
30. Mollick JA, Miller GG, Musser JM, Cook RG, Grossman D, Rich RR. A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C. J Clin Invest. 92:1993;710-719.
31. Norrby-Teglund A, Newton D, Kotb M, Holm SE, Norgren M. Superantigenic properties of the group A streptococcal exotoxin SpeF (MF). Infect Immun. 62:1994;5227-5233.
32. Kamezawa Y, Nakahara T, Nakano S, Abe Y, Nozaki-Renard J, Isono T. Streptococcal mitogenic exotoxin Z, a novel acidic superantigenic toxin produced by a T1 strain of Streptococcal pyogenes. Infect Immun. 65:1997;3828-3833.
33. Watanabe-Ohnishi R, Aelion J, LeGros L, Tomai MA, Sokurenko EV, Newton D, Takahara J, Irino S, Reshed S, Kotb M. Characterization of unique human TCR-Vβ specificities for a family of streptococcal superantigens represented by rheumatogenic serotypes of M protein. J Immunol. 152:1994;2066-2073.
34. Donaldson PM, Naylor B, Lowe JW, Gouldesbrough DR. Rapidly fatal necrotising fasciitis caused by Streptotoccus pyogenes. J Clin Pathol. 46:1993;617-620.
35. Lamothe F, D'Amico P, Ghosn P, Tremlay C, Braidy J, Patenaude JV. Clinical usefulness of intravenous human immunoglobulins in invasive group A streptococcal infections: case report and review. Clin Infect Dis. 21:1995;1469-1470.
36. Lancefield RC. Current knowledge of type-specific M antigens of group A streptococci. J Immunol. 89:1962;307-313.
37. Uchiyama T, Kamagata Y, Yan XJ, Kohno M, Yoshioka M, Fujikawa H, Igarashi H, Okubo M, Awano F, Saito-Taki T, Nakano M. Study of the biological activities of toxic shock syndrome toxin-1. II. Induction of the proliferative response and the interleukin 2 production by T cells from human peripheral blood mononuclear cells stimulated with the toxin. Clin Exp Immunol. 68:1987;638-647.
38. Uchiyama T, Imanishi K, Saito S, Araake M, Yan XJ, Fujikawa H, Igarashi H, Kato H, Obata F, Kashigawi N, Inoko H. Activation of human T cells by toxic shock syndrome toxin-1: the toxin-binding structures expressed on human lymphoid cells acting as accessory cells are HLA class II molecules. Eur J Immunol. 19:1989;1803-1809.
39. Takahashi N, Nishida H, Kato H, Imanishi K, Sakata Y, Uchiyama T. Exanthematous disease induced by toxic shock syndrome toxin-1 in the early neonatal period. Lancet. 351:1998;1614-1619.
40. Uchiyama T, Miyoshi-Akiyama T, Kato H, Fujimaki W, Imanishi K, Yan XJ. Superantigenic properties of a novel mitogenic substance produced by Yersinia pseudoÍtuberculosis isolated from patients manifesting acute and systremicc symptoms. J Immunol. 151:1993;4407-4413.
41. Miyoshi-Akiyama T, Abe A, Kato H, Kawahara K, Narimatsu H, Uchiyama T. DNA sequencing of the gene encoding a bacterial superantigen, Yersinia pseudotuberculosis -derived mitogen (YPM), and characterization of the gene product, clond YPM. J Immunol. 154:1995;5228-5234.
42. Suzuki J, Kobayashi S, Kagaya K, Fukuzawa Y. Heterogeneity of hemolytic efficiency and isoelectoric point of streptolysin O. Infect Immun. 56:1988;2474-2478.
43. Terai M, Miwa K, Williams T, Kabat W, Fukuyama M, Okajima Y, Igarashi H, Shulman ST. The absence of evidence of staphylococcal toxin involvement in the pathogenesis of Kawasaki disease. J Infect Dis. 172:1995;558-561.
44. Ohara-Nemoto Y, Kaneko M. Expression of T-cell receptor V beta 2 and type 1 helper T-cell-related cytokine mRNA in streptococcal pyrogenic exotoxin-C-activated human peripheral blood mononuclear cells. Can J Microbiol. 42:1996;1104-1111.